



Kura Oncology to Participate in Three Investor Conferences in September

September 1, 2026

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences:

Wells Fargo Healthcare Conference

September 8, 2026

3:45 p.m. ET / 12:45 p.m. PT

Cantor Global Healthcare Conference

September 9, 2026

9:10 a.m. ET / 6:10 a.m. PT

Morgan Stanley Global Healthcare Conference

September 16, 2026

7:45 a.m. ET / 4:45 a.m. PT

Live audio webcasts will be available in the Investors section of Kura's website at <https://kuraoncology.com/>, with archived replays available following all three events.

About Kura Oncology

Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura's pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory *NPM1*-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at <https://kuraoncology.com/> and follow us on [X](#) and [LinkedIn](#).

Kura Contact

Investors and Media:

Greg Mann

858-987-4046

gmann@kuraoncology.com

